Table 5.
Univariate and multivariate Cox regression analyses for different variables and OS in LARC patients.
| Variables | Overall survival (n=120) | |||
|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | |||
| HR (95% CI) | p | HR (95% CI) | p | |
| Age (≤55 vs. >55years ) | 4.778 (0.570-40.067) | 0.149 | ||
| Gender ( male vs. female) | 0.030 (0.000-36.221) | 0.334 | ||
| Clinical stage ( T3 vs. T4) | 1.941 (0.430-8.756) | 0.388 | ||
| Clinical stage ( N0 vs. N1 vs. N2) | 1.345 (0.426-4.245) | 0.614 | ||
| Tumor location ( low vs. mid vs. high) | 1.675 (0.454-6.178) | 0.439 | ||
| Tumor differentiated ( poorly vs. moderately vs. well) | 0.232 (0.068-0.794) | 0.020 | 0.232 (0.068-0.794) | 0.020 |
| CRM ( positive vs. negative) | 0.256 (0.050-1.326) | 0.105 | ||
| EMVI ( positive vs. negative) | 0.298 (0.058-1.538) | 0.148 | ||
| EGFR (positive vs. negative vs. N/A) | 0.457 (0.138-1.515) | 0.200 | ||
| MMR ( pMMR vs. dMMRvs. N/A) | 0.327 (0.057-1.888) | 0.211 | ||
| Her-2 (positive vs. negative vs. N/A) | 0.356 (0.064-1.979) | 0.238 | ||
| Radiation dose ( 45Gy vs. 50.4Gy) | 1.321 (0.293-5.945) | 0.717 | ||
OS, overall survival; LARC, locally advanced rectal cancer; CRM, circumferential resection margin; EMVI, extramural venous invasion; EGFR, epidermal growth factor receptor; MMR, mismatch repair; dMMR, mismatch-repair-deficient; pMMR, mismatch-repair-proficient; N/A, not applicable; Her-2, human epidermal growth factor receptor-2.